RedHill Biopharma has finalized a $10.5 million judgment against Kukbo Co. Ltd. The judgment includes an $8.6 million award for breach of contract and $1.9 million in legal fees and expenses, both with accrued interest. The main award is now enforceable; the legal‑fees portion remains subject to appeal until March 13 2026.
The judgment stems from Kukbo’s failure to pay under a 2021 Subscription Agreement and a 2022 Exclusive License Agreement related to RedHill’s investigational drug Opaganib. Kukbo’s counterclaims of breach, fraudulent inducement, and misrepresentation were rejected by the court.
The enforcement allows RedHill to seek foreign recognition and prevents Kukbo from disposing of assets. The company also secured a Korean court attachment grant to block asset disposal.
The $10.5 million inflow is significant for RedHill, which reported a net loss of $4.1 million for the first half of 2025 and a cash balance of $3 million as of June 30 2025. The judgment is expected to strengthen liquidity and support ongoing commercial and development activities, including the Talicia product and Opaganib program.
RedHill’s market capitalization remains small, around $4.3 million, and the company has faced Nasdaq compliance issues. The judgment reinforces its legal standing and may deter future disputes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.